(Q63843363)

English

Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

title

Phase III Randomized Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (English)

0 references

0 references

0 references

0 references

0 references

May 2012

0 references

end time

30 October 2016

0 references

number of participants

544

0 references

clinical trial phase

phase III clinical trial

0 references

minimum age

18 year

0 references

maximum age

85 year

0 references

study type

interventional study

0 references

Identifiers

ClinicalTrials.gov ID

NCT01613846

0 references

(Q63843363)

Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)